

**FORM PTO - 1449** 

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: FJN-077 RECEIVED

APPLICANTS: Tani et al.

AUG 0 6 2001

SERIAL NO.: 09/423,905

TECH CENTER 1 500/2900

					FILING D	ATE: No	vember 1	6, 1999		
			U.S	S. PATENT I	OOCUMI	ENTS		-		
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME			CLASS	SUB CLASS		ING DATE IF PROPRIATE
PAO	AB	3,904,753	09/09/75	Sonenberg	et al.		424 .	177		
PAD	AC	4,481,137	11/06/84	Ohnishi et a	ıl.		260	112		
740	AD	5,328,836	07/12/94	Shima et al.			435	69.4		
Pan	AE	5,432,267	07/11/95	Kusama et a	ıl.		536	17.9		
PAO	AF	5,510,327	04/23/96	Hayasaka et	al.		514	8		
PAD	AG	5,648,233	07/15/97	Yamaguchi	et al.		435	69.1		•
PAO	AH	5,658,742	08/19/97	Higashio et	al.		435	7.9		
PAD	AI	5,714,461	02/03/98	Masunaga e	t al.		514	8		
PAD	AJ	5,821,223	10/13/98	Rubin et al.			514	12		
PAD	AK	5,998,370	12/07/99	Arai			514	12		
			FORE	IGN PATEN	T DOCU	MENTS				
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRA ONLY	ACT	ENGLISH LANG

			FORE	IGN PATEN	T DOCU	<b>IMENTS</b>			
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
(PAN)	ВС	0 612 530 B1	8/11/00	EP	A61K	37/02	2/22/94		
PAD	BD	0 672 685 A2	9/20/95	EP	C07K	16/22	3/17/95		
P40	BE	0 891 778 A2	1/20/99	ЕР	A61K	38/18	7/9/98		
RAG	BF	0 821 969 A2	2/4/98	ЕР	A61K	38/18	7/16/93		
PAS	BG	0 588 477 A2	3/23/94	ЕР	A61K	37/02	7/16/93		
740	ВН	0 519 728 A2	12/23/92	ЕР	C12P	21/08	6/19/92		
DAO	BI	0 461 560 B1	11/18/98	EP	C12N	15/19	6/7/91		
DA9	ВЈ	0 462 549 B1	8/28/96	ЕР	C07K	2/00	6/18/91		
RAO	BK	0 456 188 A1	11/13/91	ЕР	C07K	15/00	05/07/91		
RAO	BL	0 322 084	06/28/89	EP	C12P	21/02	06/08/88		
PAO	ВМ	0 982 037 A1	01/03/00	EP	A61K	38/17	03/19/99	<del></del>	



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: FJN-077

FILING DATE: November 16, 1999

APPLICANTS: Tani et al.

SERIAL NO.: 09/423,905 ·

RECEIVED

AUG 6 2001

										4
pans.	BN	0 925 791 A1	06/30/99	EP	A61K	38/22	03/20/98			FR 1600/290
PAD	во	WO98/41230	9/24/98	PCT	A61K	38/22	3/11/98	(FJN-066)	Abstract	Jahin.
Pan	BP	WO98/40096	9/17/98	PCT	A61K	38/22	3/11/98	(FJN-065)	truslation	includeur.
DAD	BQ	WO96/20004	7/4/96	PCT	A61K	38/18	12/27/95			
RAO	BR	WO91/03254	3/21/91	PCT	A61K	37/36	9/7/90			
PAO	BS	10-194986	7/28/98	JP	A61K	38/22	6/10/97		Eng. Abst	ract
PAD	вт	10-29951	2/3/98	JP	A61K	38/27	7/12/96			
PAO	BU	6-116299	4/26/94	JP	C07K	15/14	10/2/92		Eng Absor	eact rack cenchided centused
PM D.	BV	5-244976	9/24/93	JP	C12P	19/26	3/4/92		Eng. Abs	recl
PAI)	ВW	6-56692	3/1/94	JP	A61K	37/02	8/10/92		translation	enchided
DAn	BX	10-273446	10/13/98	JP JP	A61K	38/00	3/28/97		transla Ti	enclosed
PAn	BY	6-40938	2/15/94	JP	A61K	37/24	7/17/92			
PAN	BZ	2218864	10/21/97	CA	A61K	38/18	10/24/96			

## OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)						
PAO	CA	Fujiwara et al. "Stimulation of Liver Growth by Exogenous Human Hepatocyte Growth Factor in Normal and Partially Hepatectomized Rats", Hepatology, 18(6):1443-1449 (1993).					
PAŋ	СВ	Gohda et al,. "Purification and Partial Characterization of Hepatocyte Growth Factor from Plasma of a Patient with Fulminant Hepatic Failure", <u>The American Society for Clinical Investigation</u> , Vol. 81, pp. 414-419 (February 1988).					
P40	СС	Raymond C. Harris, "Growth Factors and Cytokines in Acute Renal Failure," Supplement to Advances in Renal Replacement Therapy, Vol. 4, No. 2, Suppl. 1, April 1997, pp. 43-53.					
PAD	CD	Higashio et al. "Identity of a Tumor Cytotoxic Factor From Human Fibroblasts and Hepatocyte Growth Factor", Biochemical and Biophysical Research Communications, 170(1):397-404 (July 16, 1990).					
PAO	CE	Higashio et al. "Tumor cytotoxic activity of HGF-SF", Experientia Supplementum, 65:351-368 (1993).					
PAD	CF	Humes et al., "Renal Tubule Cell Repair following Acute Renal Injury," Mineral and Electrolyte Metabolism, Vol. 21, July - October 1995, pp. 353-365.					
PAD	CG	Kinosaki et al. "Identification of heparin-binding stretches of a naturally occurring deleted variant of hepatocyte growth factor (dHGF)", <u>Biochimica et Biophysica Acta</u> , 1384(1): 93-102 (1998).					



FORM PROMATE

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: FJN-077

RECEIVED.

APPLICANTS: Tani et al.

ALIG U 6 2001

SERIAL NO.: 09/423,905

FILING DATE: November 16, 1999 TECH CENTER 600/2900

		FILING DATE: November 16, 1999   EUH UENTER
PAI)	СН	Kinosaki et al. "Analysis of deleted variant of hepatocyte growth factor by alanine scanning mutagenesis: identification of residues essential for its biological function and generation of mutants with enhanced mitogenic activity on rat hepatocytes," <u>FEBS Letters</u> , 434(1-2):165-169 (1998).
PAO	CI	Masunaga et al. "Amelioration of Disordered Hepatic Protein Synthesis by the Deleted Form of Hepatocyte Growth Factor in Models of Liver Failure in Rats", <u>Journal of Pharmacy and Pharmacology</u> , 48:876-879 (1996).
PAD	CJ	Masunaga et al. "Deleted form of hepatocyte growth factor (dHGF) increases the number of platelets in rats with liver cirrhosis", <u>Liver</u> , 17(4):192-197 (1997).
PAO	CK	Masunaga et al., "Preventive effects of the deleted form of hepatocyte growth factor against various liver injuries," <u>European Journal of Pharmacology</u> , Vol. 342, 1998, pp. 267-279.
PAD	CL	Matsuda et al., "Hepatocyte Growth Factor Suppresses the Onset of Liver Cirrhosis and Abrogates Lethal Hepatic Dysfunction in Rats," J. Biochem, Vol. 118, No. 3, 1995, pp. 643-649.
pas	СМ	Matsumoto et al., "HGF: its organotrophic role and therapeutic potential," Therapeutic Potential of HGF, pp. 198-214.
Pan	CN	Matsumoto et al., "Roles of HGF as a pleiotropic factor in organ regeneration", <u>Hepatocyte Growth Factor-Scatter Factor</u> , (1993).
PAO	СО	Miyazawa et al., "Molecular Cloning and Sequence Analysis of cDNA for Human Hepatocyte Growth Factor", 164(2):967-973 (September 15, 1989).
PAD	СР	Morimoto et al. "Hepatocyte Growth Factor Modulates Migration and Proliferation of Human Microvascular Endothelial Cells in Culture", <u>Biochemical and Biophysical Research Communications</u> , 179(2):1042-1049 (September 16, 1991).
Pan	CQ	Nagoshi et al. "Hepatocyte apoptosis and hepatic expression of transforming growth factor-β mRNA during involution of hyperplastic rat liver induced by hepatocyte growth factor", <u>Journal of Gastroenterology and Hepatology</u> 13(8):786-793 (1998).
PAD	CR	Rubin et al., "A Broad-Spectrum Human Lung Fibroblast-Derived Mitogen is a Variant of Hepatocyte Growth Factor," Proc. Natl. Acad. Sci. USA, 88: 415-419 (1991).
PAY	CS	Francesco Paolo Schena, "Role of growth factors in acute renal failure," <u>Kidney International</u> , Vol. 53, Suppl. 66, 1998, pp. S-11-S-15.
RAD	СТ	Seki et al., "Isolation and Expression of cDNA for Different Forms of Hepatocyte Growth Factor From Human Leukocyte," <u>Biochemical and Biophysical Research Communications</u> , 172(1): 321-327 (1990).
pro	CU	Shima et al., "Possible Involvement of p21/waf1 in the Growth Inhibition of HepG2 Cells Induced by Hepatocyte Growth Factor", <u>Journal of Cellular Physiology</u> , 177(1):130-136 (1998).
PAD	CV	Shima et al. "Hepatocyte Growth Factor and its Variant with a Deletion of Five Amino Acids are Distinguishable in their Biological Activity and Tertiary Structure", <u>Biochemical and Biophysical Research Communications</u> , 200(2):808-815 (April 29, 1994).



FORM TOP 1449

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: FJN-077

APPLICANTS: Tani et al.

RECEIVED

SERIAL NO.: 09/423,905

AUG 0 6 2001

FILING DATE: November 16, 1999 TECH CENTER 1800/2900

			FILING DATE: November 16, 1999 TECH CENTER 16,00
	PAO	CW	Shima et al. "Tumor Cytotoxic Factor/Hepatocyte Growth Factor from Human Fibroblasts: Cloning of its cDNA, Purification and Characterization of Recombinant Protein", <u>Biochemical and Biophysical Research Communications</u> , 180(2):1151-1158 (October 31, 1991).
	P40	CX	Shima et al. "ELISA for F-TCF (human hepatocyte growth factor/hHGF)/fibroblast-derived tumor cytotoxic factor antigen employing monoclonal antibodies and its application to patients with liver diseases", Gastroenterologia Japonica, 26(4):477-482 (1991).
	PAR	CY	Shima et al. "A Fibroblast-Derived Tumor Cytotoxic Factor/F-TCF (Hepatocyte Growth Factor/HGF) Has Multiple Functions in Vitro", Cell Biology International Reports, 15(5):397-407 (1991).
	P45	CZ	Shima et al., "Structure of Tumor Cell Damage Factor (FTCF) and Various Bioactivity" Vol. 50, No. 8, 1992, pp. 270-274, with abstract. English Abstract in 8
	PAD	CAA	Shiota et al., "Hepatocyte Growth Factor Inhibits Growth of Hepatocellular Carcinoma Cells", Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 373-377 (January 1992).
	Paro	CAB	Tajima et al., "Hepatocyte Growth Factor has Potent Anti-Proliferative Activity in Various Tumor Cell Lines", Federation of European Biochemical Societies, 291(2):229-232 (October 1991).
=		CAC	Takehara et al., "Structure of Hepatic Cell Growth Factor (HGF) and Physiological Effect," Protein,  Nucleic Acid and Enzyme, Vol. 36, No.7, 1991, pp. 265-274.  No lnghigh Historia
		CAD	Tamakuma et al., "Cancerous Cachexia and Cachectin," Strides of Medicine, 149(5): 371-373 (1989).
	PAN	CAE	Uematsu et al., "Effective Administration Route for the Deleted Form of Hepatocyte Growth Factor to Exert its Pharmacological Effects," <u>Journal of Pharmaceutical Sciences</u> , 88(1):131-135 (January, 1999).
	Pas	CAF	Weidner et al., "Evidence for the Identity of Human Scatter Factor and Human Hepatocyte Growth Factor", Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 7001-7005 (August 1991).
	Dam	CAG	Yamaguchi et al. "Recombinant Human Hepatocyte Growth Factor Facilitates Biliary Transport After Hepatocyte Transplantation in Eisai Hyperbilirubinemic Rats", <u>Digestive Diseases and Sciences</u> , 42(3):522-528 (March 1997).
to copy pr	rided	САН	Yamashita et al. "Effects of the Deleted Form of Hepatocyte Growth Factor on Serum Hyaluronate Levels in Rats with Liver Cirrhosis", Journal of Veterinary Medical Science, 60(3):359-360 (1998).
	PAO	CAI	Yano et al. "Natural hepatocyte growth factor (HGF) from human serum and a bound form of recombinant HGF with heparan sulfate are indistinguishable in their physiochemical properties", International Journal of Biological Macromolecules, 23(3):227-235 (1998).
•	PAD	CAJ	Yasuda et al. "Antifibrogenic Effect of a Deletion Variant of Hepatocyte Growth Factor on Liver Fibrosis in Rats", Hepatology, 24(3):636-642 (1996).

2145453

PATRICIA A DUFFY

4/9/02